Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation

Breast Cancer Clinical Trial

Official title: Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation

Status Completed

Clinical Trial Summary

We continue to collect information in support of the hypothesis that the histology of the first draining lymph node (sentinel node) accurately predicts the histology of the rest of the axillary lymph nodes.

Clinical Trial Description

Using a technique combining Technetium-99 sulfur colloid and Lymphazurin Blue Dye, we have established that the sentinel node predicts the pathology results of the rest of the axillary lymph nodes. This minimally invasive technique, which can be readily performed under local anesthesia, makes the need for full axillary lymph node dissection unnecessary for most patients. If the sentinel node is negative, no further surgery is necessary. If positive, a complete axillary node dissection is performed. In addition, the injections are made while the patient is under anesthesia, reducing the physical and psychological pain that accompanies injections done pre-operatively. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer

• NCT number: NCT00575744
• Study type: Interventional
• Source: University of Arkansas
• Status: Completed
• Phase: Phase 2
• Start date: December 1998
• Completion date: October 2011